Loading stock data…
$2.41-0.10 (-3.98%)
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes.
Genprex, Inc. in the Healthcare sector is trading at $2.41 with a market capitalization of $3M. The stock is currently near its 52-week low of $2.37, remaining 89.5% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 21 is oversold, raising the odds of a near-term bounce. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$4.48M↑ | -$4.49M↓ | -$3.52M↓ | -$3.35M↑ | -$4.68M |
| Net Income | -$4.45M↑ | -$4.46M↓ | -$3.79M↑ | -$3.80M↑ | -$4.67M |
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations...